AEZS Aeterna Zentaris Inc

According the World Health Organization, cancer will become the leading cause of death worldwide this year. Cancer has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides equity research on AEterna Zentaris, Inc. (NASDAQ: AEZS) and Celsion Corporation (NASDAQ: CLSN). Access to the full company reports can be found at:

www.bedfordreport.com/AEZS www.bedfordreport.com/CLSN

Citing agency officials, The Wall Street Journal reported this month that the Food and Drug Administration (FDA) has approved 20 new drugs so far this year -- just one short of the total for all of 2010. Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Bedford Report releases stock research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Research from BioMed Tracker and BIO claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards.

AEterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. Earlier this week the company said that it "reached a key milestone" in the non-clinical development of its prostate cancer vaccine candidate, AEZS-120, for oral administration.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: The Bedford Report Email Contact